Listen: Pfizer spends $11.4B to buy Array BioPharma for its cancer drug
"Buying a Ray bio pharma in a deal worth nearly eleven and a half billion dollars array bio pharma. And if you're a shareholder congrats stocks up close to six sixty percent on this buyout. They do a bunch of things. I'm assuming that Pfizer bought a Ray for the cancer treatment portfolio. Absolutely. And it it's considered continuing a trend. We've seen it lately. With murky light lily Bristol-Myers several acquisitions in the cancer space array, specifically has to drugs in their pipeline that focused on medicines met test static easy for me to say melanoma, and I think that is the primary reason that Pfizer got interested here, obviously, eleven billion dollar price tag as you said, a sixty two. Percent premium pretty pretty pretty steep price to pay. But, you know, cancer is really where a lot of these companies, these companies are going moving away from the heart medicines. And some of the other things from the past and focusing on cancer, and I've also seen a lot of acquisitions in the gene, editing. Space, gene therapy as well looking towards what the future of medicine will be. So it's a it's a big deal. It won't add to earnings anytime soon. I think we're looking at twenty twenty two typically when you see an acquisition of a clothing, normal company, a non biotech company, you love to see the company say, it will be creative additive to earnings immediately. Sometimes not immediately. Maybe a year in this case. It's biotech. Right. They're they're not profitable. They won't be profitable for a while. So this is not going to add anything for a while. But obviously Pfizer thinks it's worth the price,"